immunotherapy malaria hemorragic fever geovax vaccines zika aids/hiv hbv lassa lasv

GeoVax Labs, Inc. (GOVX-OTC) Nominated for 2019 ViE Awards in Three categories


GeoVax announced that it has been nominated for the 2019 ViE (Vaccine Industry Excellence) Awards in three categories. Please use the following link to vote for these special industry awards in the follow categories:

  • Best Vaccine Technology/Platform
  • Best Therapeutic Vaccine
  • Best Prophylactic Vaccine
GeoVax_Logo_Clear_1.jpgGeoVax's development programs are importantly focused on vaccines against HIV as well as Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy and for therapeutic use in chronic Hepatitis B infections. .

For more information on GeoVax, please read to our most recent Quarterly Update dated November 14, 2018, as well as our Executive Informational Overview (EIO), issued on June 15, 2017 and available for download below.

Download Update 



Visit our Corporate Profile and Key Points pages

for the latest research on GeoVax Labs, Inc.